| 產(chǎn)品名稱(chēng) | Pirfenidone - AMR-69 |
| 產(chǎn)品貨號(hào) | Axon 2647 CAS [53179-13-8] MF C12H11NOMW 185.22 Purity: 100% Soluble in DMSO Description Orally available agent with therapeutic potential for idiopathic pulmonary fibrosis (IPF; IC50 value 14.44 mM for inhibition of cell proliferation against MRC-5 cells) that has combined anti-inflammatory, antioxidant and antifibrotic effects in experimental models of pulmonary fibrosis. Mechanistically, Pirfenidone inhibits not only TGF-β-induced Smad3, p38 and Akt phosphorylation in human lung fibroblasts (HLFs), but also significantly increased RGS2 mRNA and protein expression in fibroblasts. KEYWORDS:?Pirfenidone | supplier | anti-inflammatory | anti-fibrosis agent | AMR-69 | AMR69 | CAS [53179-13-8] | Immunology | idiopathic | pulmonary fibrosis | IPF | antioxidant | antifibrotic | TGF-β | Smad3 | p38 | Akt | RGS2 |
| 產(chǎn)品價(jià)格 | 現(xiàn)貨詢(xún)價(jià)，電話(huà)：010-67529703 |
| 產(chǎn)品規(guī)格 | |
| 產(chǎn)品品牌 | axonmedchem |
| 產(chǎn)品概述 | |
| 產(chǎn)品詳情 |
Pirfenidone - AMR-69Axon 2647 CAS [53179-13-8] MF C12H11NO
DescriptionOrally available agent with therapeutic potential for idiopathic pulmonary fibrosis (IPF; IC50 value 14.44 mM for inhibition of cell proliferation against MRC-5 cells) that has combined anti-inflammatory, antioxidant and antifibrotic effects in experimental models of pulmonary fibrosis. Mechanistically, Pirfenidone inhibits not only TGF-β-induced Smad3, p38 and Akt phosphorylation in human lung fibroblasts (HLFs), but also significantly increased RGS2 mRNA and protein expression in fibroblasts. KEYWORDS:?Pirfenidone | supplier | anti-inflammatory | anti-fibrosis agent | AMR-69 | AMR69 | CAS [53179-13-8] | Immunology | idiopathic | pulmonary fibrosis | IPF | antioxidant | antifibrotic | TGF-β | Smad3 | p38 | Akt | RGS2
Broad-spectrum anti-inflammatory and anti-fibrosis agent
Chemical name5-methyl-1-phenylpyridin-2(1H)-one Parent CAS No.[53179-13-8] |
| 產(chǎn)品資料 |
